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This study examined the relations among beta-adrenergic
blacker use, various correlates of left ventricular function
and the chance of developing congestive heart failure in
patients after myocardial infarction . The study was per-
formed with the placebo group of the Mulliceater Diltiazem
Post-Infarction Trial . Ejection fraction data were available
in 1,084
patients ; of these, 557 were receiving a beta .
blacker and 527 were not . In addition to ejection fraction,
other correlates of left ventricular function included the
presence or absence of pulmonary rates, chest X-ray flat
evidence of pulmonary congestion and the presence of ere S,
gallop.
Beta-blacker use was less frequent in patients with an
ejection fraction <30%, rates, an S 3 gallop and pulmonary
congestion on chest X-ray him
. Twenty-one percent of
patients with an ejection fraction <30% . 42% of patients
with rain, 20% of patients with an S, gallop and 28% of
patients with pulmonary congestion were receiving beta .
blacker therapy. For every correlate of left ventricnler
function, the chance of developing congestive heart failure
was greater In patients with diminished left ventricular
function than in those without . For each level of full
Beta-adrenergic blocking agents have been shown to de-
crease mortality after myocardial infarction (1-5) . Questions
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ventricular function, the chance of developing congestive
heart failure requiring treatment was greater in patients
not taking a beta-blocker. The 2 .5 year risk of congestive
heart failure for patients receiving beta-hlocker therapy
was 46% for those with ejection fraction <30%, 23% for
those with rates, 45% for those with S3 gallop and 37% for
those with pulmonary congestion
; the risk for patients not
receiving beta-hiocker therapy was 61%, 43%, 55% and
52.5% . respectively.
The mortality risk was less for patients receiving beta-
blocker therapy far every correlate of left ventricular
function except S, gallop. The 2.5 year risk of death for
patients receiving beta-blocker therapy was 23 .5% for
those with ejection fraction <30%, 16% for those with
rates, 40.5% ror those with S3 gallop and 13% for those
with pulmonary congestion ; the mortality risk for patients
not taking a beta-blocker was 45%, 24%, 27% and 30%,
respectively. These results, together with other informa-
tion, may encourage the cautious use of beta-hlockers in
patients with decreased NO ventricular function .
(J Am Colt Cordial 1990;16:1327-32)
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concerning their use in patients with congestive heart failure
have been raised (6). The Beta-Blocker Heart Attack Trial
(SHAT) (7) performed a subgroup analysis and examined the
outcome of patients with mechanical or pump complications.
Patients with mechanical complications had the highest
mortality and also the highest incidence
of adverse effects .
They experienced an intermediate relative benefit of ther-
apy . between those with no complications and those with
electrical complications. Another study (8) examined the
prevalence and significance of congestive heart failure in the
total BHAT population
. This retrospective analysis con-
cluded that the use of propranolol was generally safe in
0735-1097
:9495350
1328
	
LICHSTEIN ET AL.
BE['A-OLOCKER USE AND VENTRICULAR FUNCTION
patients after myocardial infarction, even in those with a
history of heart failure .
These previous studies all used various clinical, and
sometimes subjective, descriptions of congestive heart fail-
ure . The Multicenter Diltiazem Post-Infarction Trial (MD-
PIT) (9) studied the use of diltiazem in patients after myo-
cardial infarction
. The placebo group continued to receive
other cardiac medications including a beta-blocker as clini-
cally indicated . Left ventricular function was evaluated by
ejection fraction, chest X-ray film and physical examination.
The purpose of this study is to examine the relations among
beta-blocker use, various correlates of left ventricular func-
tion, particularly left ventricular ejection fraction, and the
chance of developing congestive heart failure .
Methods
Patient population
. The Multicenter Diltiazem Post-
Infarction Trial (MDPIT) enrolled patients from 23 centers in
the United States and Canada. The details of patient recruit-
ment, follow-up and statistical analysis are reported else-
where (9) . This study was performed on the placebo group of
the MDPIT . In summary, patients of either gender between
25 and 75 years of age with documented acute myocardial
infarction were eligible for the trial . Patients were randomly
assigned to either diltiazem or placebo in a double-blind
manner 3 to 15 days after the onset of myocardial infarction
while the patient was in the hospital . A permuted block
randomization procedure was used to assure a balance
between treatments within each enrolling hospital (10). The
randomization procedure also included blocking within each
hospital on number of days from myocardial infarction to
randomization (<_5 days or >5 days), current beta-
adrenergic blocker use (yes or no) and New York Heart
Association functional class I month before hospitalization
(I or 11 to IV) . Radionuclide ejection fraction was obtained
whenever possible before the initiation of trial medication .
The patients underwent follow-up examination every 4
Jnonihs . All study patients were followed up for w 12 months
up to a maximum of 52 (average 25)
. The primary end points
of interest were total mortality and first recurrent cardiac
event (cardiac death or nonfatal myocardial infarction) . The
study protocol was approved by the Committee of Human
Research at each participating center, and all participants
gave informed consent .
Correlates of left ventricular function . Additional infor-
mation, including left ventricular function, was obtained at
the time of baseline examination. This included the presence
of pulmonary rates and 5
3 gallop . The presence or absence of
pulmonary congestion was noted on a chest X-ray film
obtained in the coronary care unit before the start of trial
medication. The study coordinator identified the X-ray films
showing the must severe pulmonary congestion, as inter-
preted by a radiologist, and coded them according to a four
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level score of severity (none, mild, moderate or severe) . For
the purpose of this analysis, pulmonary congestion and rates
were classified as two level variables (none or some).
Beta-blocker data
. Information concerning beta-blocker
use was also obtained at baseline . There was no information
available concerning the reason for beta-blocker use . Con-
gestive heart failure was listed as present if symptoms
requiring treatment with diuretics or afterload-reducing
agents were noted on a clinic visit .
We investigated the relation between beta-blocker use at
randomization and the development of congestive heart
failure severe enough to require treatment
. Kaplan-Meier 2 .5
year survival (time to event) estimates were generated to
compare among patients randomized to placebo the proba-
bility of occurrence over time of congestive heart failure in
those patients who were or were not receiving a beta-blocker
at randomization . To adjust for left ventricular dysfunction,
separate time to event curves were obtained for patients in
three ejection fraction categories : <30clo , 30% to 39% and
w40%a. Cross-classification by beta-blocker use at random-
ization resulted in six curves . The relative risk of developing
congestive heart failure requiring treatment for patients who
were or were not receiving beta-blocker therapy was calcu-
lated separately for patients in each ejection fraction cate-
gory . The 95% confidence intervals for the relative risks
were also obtained .
Data analysts. This same technique was used to adjust for
the other indexes of left ventricular function, each dichoto-
mized as yes or no for pulmonary congestion, roles and S 3
gallop. For each of these indexes, four curves were obtained
(presence or absence of factor cross-classified by beta-
blocker use at randomization) . The relative risk of develop-
ing congestive heart failure for patients who were or were
not receiving a beta-blocker was calculated separately for
patients in each category of these three correlates of left
ventricular function . The 95% confidence intervals for the
relative risks were also obtained . If the confidence interval
failed to include a value of 1, then there was a significant
difference at the 5% level .
This entire set of Kaplan-Meier analyses was repeated
using all-cause mortality as an end point. (Note that there are
fewer patients in the analyses using the congestive heart
failure end point . This is because patients who had no
follow-up visits, and therefore could not be assessed for
congestive heart failure, were excluded from the congestive
heart failure analysis .
Results
Beta-blocker use and correlates of left ventricular function
(Table 1) . According to each of the correlates listed in Table
I . there was a significant association between beta-blocker
use and left ventricular function . Relative risk was used as
IACC Val . 1 6, No .6
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Table I- Relation Between Beta-Blacker Use and Various Correlates of Left
Ventricular Dysfonelion
the correlate of association. Beta-blockers were prescribed
less when there was evidence of left ventricular dysfunction .
Beta-blocker use and congestive heart failure (Table 2) .
The probabilities of developing congestive heart failure
requiring treatment by 2.5 years after randomization for the
patient groups were examined . Also shown in Table
2 are the
relative risks (the ratios of the 2.5 year risk of developing
congestive heart failure requiring therapy for patients receiv-
ing a beta-blocker to the 2.5 year risk for patients not
receiving a beta-blocker) and the
95% confidence intervals
for these relative risks
. Figure I shows the Kaplan-Meier
curves for the effects of beta-blockers on congestive heart
failure stratified by ejection fraction .
For each index of left ventricular function and for each
Beta-Rlocker Use
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'A relative risk <1 .0 indicates a lower likelihood of having (the indicator for) left ventricular dysfunction far
patients taking a bola-blocker : +comparison made with the group with on ejection fraction 440% .
stratum of each index, the risk of developing congestive
heart failure requiring therapy was less for patients on
beta-blocker therapy . Thus, we can say with certainty that,
after adiusting for left ventricular function, the risk of
developing congestive heart failure is less for patients receiv-
ing than for patients not receiving a beta-blocker .
Beta-blocker use and mortality (Table 3). As with conges-
tive heart failure, the mortality risk at 2 .5 years is less for
patients receiving than for those not receiving a beta-blocker
for each stratum of each left ventricular function index, with
the exception of the group with an S S gallop, the stratum
having the smallest number of patients . Thus, we can say
that, in general, mortality risk is less for patients receiving
than for those not receiving beta-blocker therapy .
Table 2, Kaplan-Meier 2.5 Year Risk of Developing Congestive Heart Failure ICHF) Requiring Treatment : Relative Risks
'A relative risk 01
.0 indicates a Iower likelihood at developing congestive heap failure for patients chug a beta-blacker.
No .
No. Recelnng '
Hero-ahxker
Relative Risk'
Cnefiden
Interval
Ejection fraction In - 1 .084)
04090 758 57
3097 to 39% 177 0.97 0.71-111+
,301/ 149 0,25 0.17-0 .771
Roles (o - 1 .229)
No 731 ss
Yes 498 42 0.68 0.39-0,78
S, gallop to = 1,2051
No
1
.116 i3
Yes
89
29 0 .37
0.24-0.58
Pulmonary congestion (a = 1
2
207)
No 959 57
Yes
'48
28 0.37 0 .29-0 .48
Yes No
Mowe
Risk*
9545
Confidence
Interval
No.
2 s Year Risk
„fCHFi -^I No.
2.5 Year Risk
of CHFOR
Ejection fraction to = 1 .064)
<30%
29
46 .2
I I) 81
.3 0 .75 10
.48, 1 .19)
30°10 10 39% 96
24 2 77
41
0 .55 (D .34, 0.88)
040%0 423 11 .1
324
9.9
0
.56 10 .38, 0.81)
Rates to = 1,2021
Yes
2D5
211
284 0 .54 10 .40, 0.74)
No 412 15 .4 300 :1 .6 0 .71 10 .50, 1.02)
Ss gallop (n = 1,1781
Yes 25 44 .7 63 55.3 0 .81 10 .47, 1 .40)
No 579
16 .0 511
29.0
0 .55 (0 .43 .0.71)
Pulmonary congestion to = 12071
Yes 70 37 .0 178 52.5 0 .70 (0
.49, 1 .01)
No 547 15 .3 4l2 23.1 0,66
(0 .49, 0.89)
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Years
Figure 1. The effects of beta-blocker therapy on congestive heart
failure (CHF)-free survival stratified by ejection fraction (%) . P =
group receiving beta-blocker therapy .
Discussion
Prevalence of congestive heart failure . There was a strong
relation bet- - teen left ventricular function and beta-
adrenergic Ls .,cker use . Patients with various clinical and
laboratory signs of left ventricular dysfunction were signifi-
cantly less likely to receive a beta-blocker after acute
myocardial infarction than those with no sign of left ventric-
ular dysfunction . The prevalence of congestive heart failure
has been examined in other trials . The Norwegian timolol
trial (4) reported a 7 .5% prevalence of congestive heart
failure in the placebo group. Friedman (11) reported a similar
frequency of congestive heart failure in several large trials of
Table 3 . Kaplan-Meier 2 .5
Year Mortality and Relative Risk
	A relative rink <I.0 indicates a lower likelihood of dying.
Beta-Blocker Use
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beta-blockers . The prevalence of left ventricular dysfunction
noted in our study varies depending on the definition used .
Only 7% of our placebo-treated patients had an S 3 gallop,
whereas 41% had pulmonary rules
. As these are rather
subjective indicators of left ventricular dysfunction, it is
useful to examine the ejection fraction, whi.a is an objective
and repeatable measure. In this study, 14% of the placebo-
treated patients had an ejection fraction <30% . Only 21% of
these patients were on beta-blocker therapy, whereas 55% of
those with an ejection fraction of 30% to 39% and 57% of
those with an ejection fraction ?40% were receiving a
beta-blocker.
Twenty-eight percent of patients with an S3 gallop and
28% with X-ray evidence of pulmonary congestion were
receiving a beta-blocker. The fraction of patients with rates
who were receiving a beta-blocker was larger (42%) than "aat
of those who were not. The greater prevalence of rules in the
study group (41% of 1,229 patients had rates), in addition to
the greater amount of beta-blacker use, suggests that the
presence of rules was not used by clinicians as a specific
marker for left ventricular dysfunction to the same extent as
ejection fraction, S 3 gallop and pulmonary congestion on
X-ray study .
The chance of developing congestive heart failure was
greater with diminished left ventricular function regardless
of which variable of left ventricular function was used . Of
particular interest was the observation that for each level of
left ventricular function, the chance of developing conges-
tive heart failure requiring treatment was greater in patients
not receiving than in patients receiving a beta blocker at the
time of randomization .
Beta-blockers in patients with cardiomyopathy. Waag-
stein et al . (12) reported the beneficial effects of long-term
LVF Index
Yes No
Relative
Risk-
95%
Confidence
Interval
No .
2.5 Year Mortality
Risk (%)
No .
2.5 Year Mortality
Risk (%I
Ejection fraction (n = 1 .084)
Q0%. 31 23.5 118 44 .6 0.53
(2
.26, 1.05)
30% to 39911 98 8 .5 79 19 .0
0
.45
(0.18 . 1.10)
040% 428 7 .7 330 12 .6 0
.61 (0
.38, 0.99)
Rates (n = 1 .229)
Yes 207 16 .4 291 23 .8 0.69 (0 .45 . 1.04)
No 422 5 .9 309 17 .4 0.34 (0 .20. 0.56)
gallop In
= 1,2051
Yes
25 40.5 64 27 .4 1 .47 (0 .69, 3 .13)
No
590 8.3 526 19.7 0.42 (0 .29, 0 .60)
Pulmonary congestion (a = 1 .207)
Yes
70 13.4 178 30.3 0 .44 (0 .22, 0 .90)
No
547 8.5 412 16.7 0 .51 10.34, 0 .761
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beta-Mocker therapy in dilated cardiomyopathy . They sug-
gested that their finding of a decrease h . .,ystemic vascular
resistance might be secondary to a decrease in circulating
epinephrine or to a decrease in levels of renin and angiolen-
sin . The ability of beta-blockers to suppress renin production
has been shown in long-term hypertension studies ( 13) . With
a decrease in left ventricular function, there is a stimulus for
increased renin due to increases in sympathetic tone and
peripheral resistance . This may also be reversed by beta-
blocker therapy .
"Up-regulation" of beta-btoekers . Greene et al . (14) re-
ported data from the Cardiac Arrhythmia Pilot Study . They
found that significant congestive heart failure was more
common in patients not receiving than in those receiving a
beta-blocker at baseline study . Although this finding sug-
gested that patients taking a beta-blocker had less left
ventricular dysfunction, comparison of ejection fraction in
the two groups showed that left ventricular function was not
significantly better in patients taking a beta-blacker
. The
authors suggested that "up-regulation" of beta-blocker den-
sity was an alternative explanation for the lack of congestive
heart failure in that group. Various studies (15) have shown
that chronic heart failure is associated with a reduction in
myocardial beta-adrenergic receptors and decreased sensi-
tivity to beta-adrenergic stimulation . Heilbronn et al . (16)
noted significant improvement in left ventricular function .
improved response to catecholamines and increases in myo-
cardial beta-receptor density in a group of patients with
dilated cardiomyopathy treated with metoprolol . It was
suggested that the increased beta-adrenergic receptor den-
sity was due to decreased catecholamine exposure caused by
receptor occupancy
. Heilbronn et al . (16) suggested that
other mechanisms could explain the benefit of beta-blockers
to the failing heart. These included prevention of calcium
overload, inhibition of free radical formation and peripheral
effects that benefit the myocardium .
Beta-blockers in patients with decreased left ventricular
function. The effects of beta-blockers in patients with de-
creased heart function can be inferred from the results of the
MIAMI study (17) . This trial examined 15 day mortality after
short-term intravenous administration of a beta-blocker after
acute myocardial infarction . The investigators analyzed their
data on the basis of risk predictors, which included history of
previous myocardial infarction, congestive heart failure and
treatment with diuretics or digitalis . Metoprolol. the beta-
blocker being studied, had no apparent effect in the low risk
group . However, in the high risk group, there was a differ-
ence in mortality rate of 29% in favor of beta-blocker
treatment . This finding is similar to the subgroup analysis of
BHAT reported by Furberg et al. ('1), who found that
patients with mechanical complication ., had a lower mortal-
ity rate with propranolol than did those receiving placebo
.
Because many patients with congestive heart failure die
suddenly, these authors suggested that the protective effects
LICHSTEIN ET AL .
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of the drug were related to its ability to decrease the
incidence of ventricular fibrillation and ventricular tachycar-
dia
. The effectiveness of the beta-blockers in decreasing
ventricular ectopic activity has been shown (18) t Brodsky et
al . (19) observed that this effectiveness is maintained in
patients with impaired left ventricular function . Furberg et
al . (7) also noted that the small group of patients with severe
mechanical complications such as pulmonary edema did not
benefit from propranolol . It was thought that these patients
had such a severe degree of myocardial depression that the
cardiodepressant actions of propranolol may have out-
weighed its favorable effects . This may be similar to the
observation in our group with an S, gallop, which was the
only subgroup without a favorable outcome on beta-blocker
therapy . Auscultation of an S, gallop in this small group of
patients may have identified those with very severe myocar-
dial damage .
Conclusions. Beta-blocker use is influenced by signs of
left sentricular dysfunction : beta-blocker use was less fre-
quent in patients with an ejection fraction <30%, rates . a n S,
gallop and pulmonary congestion on X-ray study . For every
correlate of left ventricular function . the chance of develop-
ing congestive heart failure was greater in patients with than
in those without diminished left ventricular function. For
each level of left ventricular function, the chance of devel-
oping congestive heart failure requiring treatment was
greater in patients receiving a beta-blocker
. With the excep-
tion of patients with an S5 gallop, the mortality risk was less
for patients on beta-blacker therapy for every correlate of
left ventricular function. These results, together with other
information, may encourage the cautious use of beta-blocker
therapy in patients with decreased left ventricular function .
When a beta-blocker is used, the dose should probably be
low initially and then increased gradually if no increase in
signs or symptoms of heart failure is noted
.
We thank Benila C . Buonanno for her secretarial assistance
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